Another lab approved for batch testing, release of Covid-19 vaccines

In an effort to ramp up the speed of vaccination in the country, the Union Health Ministry has approved another laboratory for testing and lot release of Covid-19 vaccines, it said on Monday

Vaccine production
(Photo: Bloomberg)
Press Trust of India New Delhi
2 min read Last Updated : Aug 17 2021 | 1:19 AM IST

In an effort to ramp up the speed of vaccination in the country, the Union Health Ministry has approved another laboratory for testing and lot release of COVID-19 vaccines, it said on Monday.

The ministry has notified the National Institute of Animal Biotechnology (NIAB) as a Central Drug Laboratory (CDL) for testing and lot release of Covid vaccines, according to an official statement.

In order to discuss the various aspects of COVID-19 vaccination distribution in India, a meeting was organised under the chairmanship of the cabinet secretary on November 11, 2020.

In the meeting, the Department of Biotechnology (DBT), Department of Science and Technology (DST), and the Council of Scientific and Industrial Research (CSIR) were asked to indicate to the Health Ministry if any of their labs could be converted for use as a CDL.

After due deliberations, the DBT proposed two laboratories, namely the NIAB and the National Centre for Cell Sciences (NCCS), Pune, for this purpose. Funds from the Prime Minister Cares Fund Trust (PM-CARES) were allotted for upgradation of these two laboratories, the statement said.

"The Central Drugs Standard Control Organisation (CDSCO) had furnished a draft notification to the Union Health Ministry for notifying NIAB, Hyderabad as a CDL laboratory in response to which the Union Health Ministry has now notified NIAB, Hyderabad as a CDL laboratory," it added.

The NCCS, Pune was notified as a CDL on June 28, 2021 by the Health Ministry, the statement said.

The notification of these two laboratories as CDLs will improve vaccine production and ultimately strengthen the vaccination campaign, it stated.

 

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineHealth Ministry

First Published: Aug 16 2021 | 7:07 PM IST

Next Story